Stefano Fanti | Università di Bologna (original) (raw)
Papers by Stefano Fanti
Clinical cancer research : an official journal of the American Association for Cancer Research, Jan 15, 2015
Purpose To evaluate the role of 18F-FDG PET/CT in 282 symptomatic MM pts treated up-front between... more Purpose To evaluate the role of 18F-FDG PET/CT in 282 symptomatic MM pts treated up-front between 2002 and 2012. Experimental design All pts were studied by PET/CT at baseline, during post-treatment follow-up and at the time of relapse. Their median duration of follow-up was 67 months. Results Forty-two percent of the pts at diagnosis had > 3 FLs and in 50% SUVmax was > 4.2; EMD was present in 5%. On multivariate analysis, ISS 3, SUVmax > 4.2 and failure to achieve best CR were the leading factors independently associated with shorter PFS and OS. These 3 variables were used to construct a prognostic scoring system based on the number of risk factors. After treatment, PET/CT negativity (PET-neg) was observed in 70% of pts, while conventionally-defined CR was achieved in 53%. Attainment of PET-neg favourably influenced PFS and OS. PET-neg was an independent predictor of prolonged PFS and OS for patients with conventionally-defined CR. Sixty-three percent of pts experienced re...
Diagnostics
Background: As reported in the literature, [18F]-fluorodeoxyglucose positron emission tomography/... more Background: As reported in the literature, [18F]-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]-FDG PET/CT) provides useful qualitative and semi-quantitative data for the prognosis of advanced differentiated thyroid cancer. Instead, there is a lack of data about the real clinical impact of 18F-FDG PET/CT on the choice of the more effective therapeutic approach for advanced differentiated thyroid cancer (DTC) that starts to lose iodine avidity. The primary aim of this retrospective study was to assess how 18F-FDG PET/CT can guide the choice of the best therapeutic approach to RAI-refractory DTC (RAI-R-DTC) in patients with a doubtful iodine uptake/negative 18F-FDG PET/CT I whole-body scan after several radioactive iodine therapies (RAIT). The secondary aim was to assess the prognostic role of clinical and semi-quantitative metabolic 18F-FDG PET/CT parameters in comparison to published data. Materials and methods: A monocentric retrospective observational s...
Hepatobiliary Surgery and Nutrition
European journal of nuclear medicine and molecular imaging, 2017
After primary treatment, biochemical relapse (BCR) occurs in a substantial number of patients wit... more After primary treatment, biochemical relapse (BCR) occurs in a substantial number of patients with prostate cancer (PCa). PET/CT imaging with prostate-specific membrane antigen based tracers (68Ga-PSMA) has shown promising results for BCR patients. However, a standardized image interpretation methodology has yet to be properly agreed. The aim of this study, which was promoted and funded by European Association of Nuclear Medicine (EANM), is to define standardized image interpretation criteria for 68Ga-PSMA PET/CT to detect recurrent PCa lesions in patients treated with primary curative intent therapy (radical prostatectomy or radiotherapy) who presented a biochemical recurrence. In the first phase inter-rater agreement between seven readers from seven international centers was calculated on the reading of 68Ga-PSMA PET/CT images of 49 patients with BCR. Each reader evaluated findings in five different sites of recurrence (local, loco-regional lymph nodes, distant lymph nodes, bone, ...
European Urology Focus, 2016
Context: To effectively manage patients with advanced prostate cancer (APC), it is essential to h... more Context: To effectively manage patients with advanced prostate cancer (APC), it is essential to have accurate, reproducible, and validated methods for detecting and quantifying the burden of bone and soft tissue metastases and for assessing their response to therapy. Current standard of care imaging with bone and computed tomography (CT) scans have significant limitations for the assessment of bone metastases in particular. Objective: We aimed to undertake a critical comparative review of imaging methods used for diagnosis and disease monitoring of metastatic APC from the perspective of their availability and ability to assess disease presence, extent, and response of bone and soft tissue disease. Evidence acquisition: An expert panel of radiologists, nuclear medicine physicians, and medical physicists with the greatest experience of imaging in advanced prostate cancer prepared a review of the practicalities, performance, merits, and limitations of currently available imaging methods. Evidence synthesis: Meta-analyses showed that positron emission tomography (PET)/CT with different radiotracers and whole-body magnetic resonance imaging (WB-MRI) are more accurate for bone lesion detection than CT and bone scans (BSs). At a patient level, the pooled sensitivities for bone disease by using choline (CH)-PET/CT, WB-MRI, and BS were 91% (95% confidence interval [CI], 83-96%), 97% (95% CI, 91-99%), and 79% (95% CI, 73-83%), respectively. The pooled specificities for bone metastases detection using CH-PET/CT, WB-MRI, and BS were 99% (95% CI, 93-100%), 95% (95% CI, 90-97%), and 82% (95% CI, 78-85%), respectively. The ability of PET/CT and WB-MRI to assess therapeutic benefits is promising but has not been comprehensively evaluated. There is variability in the cost, availability, and quality of PET/CT and WB-MRI. Conclusions: Standardisation of acquisition, interpretation, and reporting of WB-MRI and PET/CT scans is required to assess the performance of these techniques in clinical trials of treatment approaches in APC. Patient summary: PET/CT and whole-body MRI scans have the potential to improve detection and to assess response to treatment of all types of advanced prostate cancer. Consensus recommendations on quality standards, interpretation, and reporting are needed but will require validation in clinical trials of established and new treatment approaches.
Society of Nuclear Medicine Annual Meeting Abstracts, May 1, 2008
Society of Nuclear Medicine Annual Meeting Abstracts, May 1, 2008
Nuclear Medicine Communications, 2013
Departments of Nuclear Medicine, Radiology and Urology, Azienda Ospedaliero-Universitaria di Bolo... more Departments of Nuclear Medicine, Radiology and Urology, Azienda Ospedaliero-Universitaria di Bologna, Policlinico S.Orsola-Malpighi, Bologna and Department of Imaging, Nuclear Medicine, Radiology, NeuroRadiology, Medical Physics, Santa Maria della Misericordia Hospital, Rovigo, Italy Correspondence to Domenico Rubello, MD, Department of Imaging, Nuclear Medicine, Radiology, NeuroRadiology, Medical Physics, Santa Maria della Misericordia Hospital, Rovigo 54100, Italy Tel: + 39 0425 39 4428; fax: + 39 0425 39 4434; e-mail: domenico.rubello@libero.it
Nuclear medicine …, 1993
The study aimed to evaluate the safety and reliability of captopril renal scintigraphy (CRS) for ... more The study aimed to evaluate the safety and reliability of captopril renal scintigraphy (CRS) for diagnosing functionally significant renal artery stenosis (RAS) in hypertensive patients with a solitary kidney. Radionuclide studies were carried out using 100 MBq 99Tcm-mercaptoacetyl triglycine (MAG3), 1 h after administration of 50 mg captopril, and repeated in baseline condition when abnormalities were observed in the provocative study. Scintigraphic diagnosis of RAS was based on analysis of captopril-induced changes of the radiorenographs. Overall, 12 patients with a solitary kidney were investigated, and scintigraphic results compared to angiographic findings. All five patients with positive CRS showed an RAS > 50%, whereas only one of the seven patients with negative CRS was affected by RAS. A significant fall in mean arterial pressure was recorded after captopril administration (123 +/- 12 mm Hg before versus 108 +/- 11 after), but no serious side effects were observed. Our results demonstrate that captopril-induced modifications of the renogram could effectively be used to diagnose the presence of RAS. Captopril renal scintigraphy may therefore be suggested as a reliable and safe noninvasive approach to evaluate hypertensive patients with a solitary kidney.
European Journal of Nuclear Medicine and Molecular Imaging, 2016
The aim of this study was to synthesize and preclinically evaluate an (18)F-PSMA positron emissio... more The aim of this study was to synthesize and preclinically evaluate an (18)F-PSMA positron emission tomography (PET) tracer. Prostate-specific membrane antigen (PSMA) specificity, biodistribution, and dosimetry in healthy and tumor-bearing mice were determined. Several conditions for the labeling of (18)F-PSMA-11 via (18)F-AlF-complexation were screened to study the influence of reaction temperature, peptide amount, ethanol volume, and reaction time. After synthesis optimization, biodistribution and dosimetry studies were performed in C57BL6 mice. For proof of PSMA-specificity, mice were implanted with PSMA-negative (PC3) and PSMA-positive (LNCaP) tumors in contralateral flanks. Static and dynamic microPET/computed tomography (CT) imaging was performed. Quantitative labeling yields could be achieved with >97 % radiochemical purity. The (18)F-PSMA-11 uptake was more than 24-fold higher in PSMA-high LNCaP than in PSMA-low PC3 tumors (18.4 ± 3.3 %ID/g and 0.795 ± 0.260 %ID/g, respectively; p < 4.2e-5). Results were confirmed by ex vivo gamma counter analysis of tissues after the last imaging time point. The highest absorbed dose was reported for the kidneys. The maximum effective dose for an administered activity of 200 MBq was 1.72 mSv. (18)F-PSMA-11 using direct labeling of chelate-attached peptide with aluminum-fluoride detected PSMA-expressing tumors with high tumor-to-liver ratios. The kidneys were the dose-limiting organs. Even by applying the most stringent dosimetric calculations, injected activities of up to 0.56 GBq are feasible.
Society of Nuclear Medicine Annual Meeting Abstracts, May 1, 2010
PET-CT: Rare Findings and Diseases, 2012
A 53-year-old male patient was referred for a 68Ga-DOTA NOC PET/CT scan (Fig. 136.1) for suspecte... more A 53-year-old male patient was referred for a 68Ga-DOTA NOC PET/CT scan (Fig. 136.1) for suspected Zollinger Ellison syndrome. The scan was negative, but increased uptake in the left sacroiliac joint, lumbar spine, ribs and skull was detected. These areas were subsequently proven to be related to multiple myeloma.
Journal of Hepatology, 2008
S153 IMA/1st IMA (P = 0.006). In ROC curve, cutoff value of 3rd IMA/1st IMA for predicting treatm... more S153 IMA/1st IMA (P = 0.006). In ROC curve, cutoff value of 3rd IMA/1st IMA for predicting treatment response was 0.786 (sensitivity 80%, specificity 100%, AUC 0.829). Conclusions: IMA was decreased significantly at 6hr after TACE in patients with HCC. If IMA level at 6hr after TACE is decreased less than 80% of baseline IMA level, good treatment response such as CR or PR might be predicted in patients with HCC.
Annals of Nuclear Medicine, 1996
Pertechnegas is a new ventilation agent produced by modifying the atmosphere of combustion of Tec... more Pertechnegas is a new ventilation agent produced by modifying the atmosphere of combustion of Technegas. Due to its rapid disappearance from the lungs, Pertechnegas has been suggested as useful in measuring pulmonary epithelial permeability. This study aimed to assess the reliability of ventilation scans with Pertechnegas to evaluate alveolar-capillary permeability. Six non-smokers with no evidence of pulmonary disease were investigated. Scintigraphic data were used to evaluate the site of Pertechnegas deposition (by assessing the Penetration Index [PI] of the gas), its clearance rate (by calculating the time to half-clearance [T1/2]) and its lung distribution (by means of a pixel-by-pixel analysis. PI measurements produced a mean value of 88.8 +/- 13.3% (range 69-117%). Time activity curves showed a fast clearance in all cases (mean T1/2 = 10.7 +/- 2.1 min, range 8.1-14.3 min). Comparison of statistical indices of uniform deposition (skewness and kurtosis) indicated satisfactory homogeneity of Pertechnegas distribution throughout the lungs. These data show that after inhalation Pertechnegas has a peripheral deposition and a homogeneous distribution in the lungs and is rapidly cleared through the alveolar-capillary barrier. In conclusion Pertechnegas can be recommended as a potential radiopharmaceutical for studying the pulmonary epithelial barrier.
BMJ Case …, 2010
A fit, 54-year-old, postmenopausal woman presented with an upper outer quadrant left breast mass ... more A fit, 54-year-old, postmenopausal woman presented with an upper outer quadrant left breast mass in October 2007, for which she underwent conservative surgery. Histology revealed a 27 mm, grade 3, oestrogen receptor (ER) positive, human epidermal growth factor receptor 2 ...
Nuclear Medicine …, 2007
The term 'molecular imaging' encompasses a range of imaging techniques that are aimed a... more The term 'molecular imaging' encompasses a range of imaging techniques that are aimed at visualizing molecular events at a cellular level in a living organism, in a non-invasive approach, to avoid exposing the subject to a surgical risk. Important molecular imaging ...
![Research paper thumbnail of A [68Ga]Ga-DOTANOC PET/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours](https://attachments.academia-assets.com/78118593/thumbnails/1.jpg)
](Diagnostics
Predicting grade 1 (G1) and 2 (G2) primary pancreatic neuroendocrine tumour (panNET) is crucial t... more Predicting grade 1 (G1) and 2 (G2) primary pancreatic neuroendocrine tumour (panNET) is crucial to foresee panNET clinical behaviour. Fifty-one patients with G1-G2 primary panNET demonstrated by pre-surgical [68Ga]Ga-DOTANOC PET/CT and diagnostic conventional imaging were grouped according to the tumour grade assessment method: histology on the whole excised primary lesion (HS) or biopsy (BS). First-order and second-order radiomic features (RFs) were computed from SUV maps for the whole tumour volume on HS. The RFs showing the lowest p-values and the highest area under the curve (AUC) were selected. Three radiomic models were assessed: A (trained on HS, validated on BS), B (trained on BS, validated on HS), and C (using the cross-validation on the whole dataset). The second-order normalized homogeneity and entropy was the most effective RFs couple predicting G2 and G1. The best performance was achieved by model A (test AUC = 0.90, sensitivity = 0.88, specificity = 0.89), followed by ...
Blood
FDG-PET role in the assessment of lymphoma patients is well established but only few papers evalu... more FDG-PET role in the assessment of lymphoma patients is well established but only few papers evaluated the usefulness of FDG-PET during follow up. Aim: to prospectively investigate the value of serial FDG-PET scans in the follow up of lymphoma patients in complete remission. All lymphoma patients who achieved a complete remission were prospectively enrolled in the study and scheduled for serial FDG-PET scans at 6, 12, 18 and 24 months; further scans were then carried out on annual basis (overall 421 pts, 160 pts with Hodgkin’s Disease (HD) and 261 pts with non-Hodgkin Lymphoma (NHL) were studied). All patients had a final assessment using other imaging procedures and/or biopsy and/or clinical evolution. FDG-PET findings were reported as positive, indeterminate or negative for relapse; after comparison with all available data, PET results were categorized as true positive (TP), true negative (TN), false positive (FP), indeterminate turned out to be relapse (I+) and indeterminate turne...
Seminars in nuclear medicine, 2016
Conventional anatomical imaging with CT and MRI has limitations in the evaluation of prostate can... more Conventional anatomical imaging with CT and MRI has limitations in the evaluation of prostate cancer. PET is a powerful imaging technique, which can be directed toward molecular targets as diverse as glucose metabolism, density of prostate-specific membrane antigen receptors, and skeletal osteoblastic activity. Although 2-deoxy-2-(18)F-FDG-PET is the mainstay of molecular imaging, FDG has limitations in typically indolent prostate cancer. Yet, there are many useful and emerging PET tracers beyond FDG, which provide added value. These include radiotracers interrogating prostate cancer via molecular mechanisms related to the biology of choline, acetate, amino acids, bombesin, and dihydrotestosterone, among others. Choline is used for cell membrane synthesis and its metabolism is upregulated in prostate cancer. (11)C-choline and (18)F-choline are in wide clinical use outside the United States, and they have proven most beneficial for detection of recurrent prostate cancer. (11)C-acetat...
Clinical cancer research : an official journal of the American Association for Cancer Research, Jan 15, 2015
Purpose To evaluate the role of 18F-FDG PET/CT in 282 symptomatic MM pts treated up-front between... more Purpose To evaluate the role of 18F-FDG PET/CT in 282 symptomatic MM pts treated up-front between 2002 and 2012. Experimental design All pts were studied by PET/CT at baseline, during post-treatment follow-up and at the time of relapse. Their median duration of follow-up was 67 months. Results Forty-two percent of the pts at diagnosis had > 3 FLs and in 50% SUVmax was > 4.2; EMD was present in 5%. On multivariate analysis, ISS 3, SUVmax > 4.2 and failure to achieve best CR were the leading factors independently associated with shorter PFS and OS. These 3 variables were used to construct a prognostic scoring system based on the number of risk factors. After treatment, PET/CT negativity (PET-neg) was observed in 70% of pts, while conventionally-defined CR was achieved in 53%. Attainment of PET-neg favourably influenced PFS and OS. PET-neg was an independent predictor of prolonged PFS and OS for patients with conventionally-defined CR. Sixty-three percent of pts experienced re...
Diagnostics
Background: As reported in the literature, [18F]-fluorodeoxyglucose positron emission tomography/... more Background: As reported in the literature, [18F]-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]-FDG PET/CT) provides useful qualitative and semi-quantitative data for the prognosis of advanced differentiated thyroid cancer. Instead, there is a lack of data about the real clinical impact of 18F-FDG PET/CT on the choice of the more effective therapeutic approach for advanced differentiated thyroid cancer (DTC) that starts to lose iodine avidity. The primary aim of this retrospective study was to assess how 18F-FDG PET/CT can guide the choice of the best therapeutic approach to RAI-refractory DTC (RAI-R-DTC) in patients with a doubtful iodine uptake/negative 18F-FDG PET/CT I whole-body scan after several radioactive iodine therapies (RAIT). The secondary aim was to assess the prognostic role of clinical and semi-quantitative metabolic 18F-FDG PET/CT parameters in comparison to published data. Materials and methods: A monocentric retrospective observational s...
Hepatobiliary Surgery and Nutrition
European journal of nuclear medicine and molecular imaging, 2017
After primary treatment, biochemical relapse (BCR) occurs in a substantial number of patients wit... more After primary treatment, biochemical relapse (BCR) occurs in a substantial number of patients with prostate cancer (PCa). PET/CT imaging with prostate-specific membrane antigen based tracers (68Ga-PSMA) has shown promising results for BCR patients. However, a standardized image interpretation methodology has yet to be properly agreed. The aim of this study, which was promoted and funded by European Association of Nuclear Medicine (EANM), is to define standardized image interpretation criteria for 68Ga-PSMA PET/CT to detect recurrent PCa lesions in patients treated with primary curative intent therapy (radical prostatectomy or radiotherapy) who presented a biochemical recurrence. In the first phase inter-rater agreement between seven readers from seven international centers was calculated on the reading of 68Ga-PSMA PET/CT images of 49 patients with BCR. Each reader evaluated findings in five different sites of recurrence (local, loco-regional lymph nodes, distant lymph nodes, bone, ...
European Urology Focus, 2016
Context: To effectively manage patients with advanced prostate cancer (APC), it is essential to h... more Context: To effectively manage patients with advanced prostate cancer (APC), it is essential to have accurate, reproducible, and validated methods for detecting and quantifying the burden of bone and soft tissue metastases and for assessing their response to therapy. Current standard of care imaging with bone and computed tomography (CT) scans have significant limitations for the assessment of bone metastases in particular. Objective: We aimed to undertake a critical comparative review of imaging methods used for diagnosis and disease monitoring of metastatic APC from the perspective of their availability and ability to assess disease presence, extent, and response of bone and soft tissue disease. Evidence acquisition: An expert panel of radiologists, nuclear medicine physicians, and medical physicists with the greatest experience of imaging in advanced prostate cancer prepared a review of the practicalities, performance, merits, and limitations of currently available imaging methods. Evidence synthesis: Meta-analyses showed that positron emission tomography (PET)/CT with different radiotracers and whole-body magnetic resonance imaging (WB-MRI) are more accurate for bone lesion detection than CT and bone scans (BSs). At a patient level, the pooled sensitivities for bone disease by using choline (CH)-PET/CT, WB-MRI, and BS were 91% (95% confidence interval [CI], 83-96%), 97% (95% CI, 91-99%), and 79% (95% CI, 73-83%), respectively. The pooled specificities for bone metastases detection using CH-PET/CT, WB-MRI, and BS were 99% (95% CI, 93-100%), 95% (95% CI, 90-97%), and 82% (95% CI, 78-85%), respectively. The ability of PET/CT and WB-MRI to assess therapeutic benefits is promising but has not been comprehensively evaluated. There is variability in the cost, availability, and quality of PET/CT and WB-MRI. Conclusions: Standardisation of acquisition, interpretation, and reporting of WB-MRI and PET/CT scans is required to assess the performance of these techniques in clinical trials of treatment approaches in APC. Patient summary: PET/CT and whole-body MRI scans have the potential to improve detection and to assess response to treatment of all types of advanced prostate cancer. Consensus recommendations on quality standards, interpretation, and reporting are needed but will require validation in clinical trials of established and new treatment approaches.
Society of Nuclear Medicine Annual Meeting Abstracts, May 1, 2008
Society of Nuclear Medicine Annual Meeting Abstracts, May 1, 2008
Nuclear Medicine Communications, 2013
Departments of Nuclear Medicine, Radiology and Urology, Azienda Ospedaliero-Universitaria di Bolo... more Departments of Nuclear Medicine, Radiology and Urology, Azienda Ospedaliero-Universitaria di Bologna, Policlinico S.Orsola-Malpighi, Bologna and Department of Imaging, Nuclear Medicine, Radiology, NeuroRadiology, Medical Physics, Santa Maria della Misericordia Hospital, Rovigo, Italy Correspondence to Domenico Rubello, MD, Department of Imaging, Nuclear Medicine, Radiology, NeuroRadiology, Medical Physics, Santa Maria della Misericordia Hospital, Rovigo 54100, Italy Tel: + 39 0425 39 4428; fax: + 39 0425 39 4434; e-mail: domenico.rubello@libero.it
Nuclear medicine …, 1993
The study aimed to evaluate the safety and reliability of captopril renal scintigraphy (CRS) for ... more The study aimed to evaluate the safety and reliability of captopril renal scintigraphy (CRS) for diagnosing functionally significant renal artery stenosis (RAS) in hypertensive patients with a solitary kidney. Radionuclide studies were carried out using 100 MBq 99Tcm-mercaptoacetyl triglycine (MAG3), 1 h after administration of 50 mg captopril, and repeated in baseline condition when abnormalities were observed in the provocative study. Scintigraphic diagnosis of RAS was based on analysis of captopril-induced changes of the radiorenographs. Overall, 12 patients with a solitary kidney were investigated, and scintigraphic results compared to angiographic findings. All five patients with positive CRS showed an RAS > 50%, whereas only one of the seven patients with negative CRS was affected by RAS. A significant fall in mean arterial pressure was recorded after captopril administration (123 +/- 12 mm Hg before versus 108 +/- 11 after), but no serious side effects were observed. Our results demonstrate that captopril-induced modifications of the renogram could effectively be used to diagnose the presence of RAS. Captopril renal scintigraphy may therefore be suggested as a reliable and safe noninvasive approach to evaluate hypertensive patients with a solitary kidney.
European Journal of Nuclear Medicine and Molecular Imaging, 2016
The aim of this study was to synthesize and preclinically evaluate an (18)F-PSMA positron emissio... more The aim of this study was to synthesize and preclinically evaluate an (18)F-PSMA positron emission tomography (PET) tracer. Prostate-specific membrane antigen (PSMA) specificity, biodistribution, and dosimetry in healthy and tumor-bearing mice were determined. Several conditions for the labeling of (18)F-PSMA-11 via (18)F-AlF-complexation were screened to study the influence of reaction temperature, peptide amount, ethanol volume, and reaction time. After synthesis optimization, biodistribution and dosimetry studies were performed in C57BL6 mice. For proof of PSMA-specificity, mice were implanted with PSMA-negative (PC3) and PSMA-positive (LNCaP) tumors in contralateral flanks. Static and dynamic microPET/computed tomography (CT) imaging was performed. Quantitative labeling yields could be achieved with >97 % radiochemical purity. The (18)F-PSMA-11 uptake was more than 24-fold higher in PSMA-high LNCaP than in PSMA-low PC3 tumors (18.4 ± 3.3 %ID/g and 0.795 ± 0.260 %ID/g, respectively; p < 4.2e-5). Results were confirmed by ex vivo gamma counter analysis of tissues after the last imaging time point. The highest absorbed dose was reported for the kidneys. The maximum effective dose for an administered activity of 200 MBq was 1.72 mSv. (18)F-PSMA-11 using direct labeling of chelate-attached peptide with aluminum-fluoride detected PSMA-expressing tumors with high tumor-to-liver ratios. The kidneys were the dose-limiting organs. Even by applying the most stringent dosimetric calculations, injected activities of up to 0.56 GBq are feasible.
Society of Nuclear Medicine Annual Meeting Abstracts, May 1, 2010
PET-CT: Rare Findings and Diseases, 2012
A 53-year-old male patient was referred for a 68Ga-DOTA NOC PET/CT scan (Fig. 136.1) for suspecte... more A 53-year-old male patient was referred for a 68Ga-DOTA NOC PET/CT scan (Fig. 136.1) for suspected Zollinger Ellison syndrome. The scan was negative, but increased uptake in the left sacroiliac joint, lumbar spine, ribs and skull was detected. These areas were subsequently proven to be related to multiple myeloma.
Journal of Hepatology, 2008
S153 IMA/1st IMA (P = 0.006). In ROC curve, cutoff value of 3rd IMA/1st IMA for predicting treatm... more S153 IMA/1st IMA (P = 0.006). In ROC curve, cutoff value of 3rd IMA/1st IMA for predicting treatment response was 0.786 (sensitivity 80%, specificity 100%, AUC 0.829). Conclusions: IMA was decreased significantly at 6hr after TACE in patients with HCC. If IMA level at 6hr after TACE is decreased less than 80% of baseline IMA level, good treatment response such as CR or PR might be predicted in patients with HCC.
Annals of Nuclear Medicine, 1996
Pertechnegas is a new ventilation agent produced by modifying the atmosphere of combustion of Tec... more Pertechnegas is a new ventilation agent produced by modifying the atmosphere of combustion of Technegas. Due to its rapid disappearance from the lungs, Pertechnegas has been suggested as useful in measuring pulmonary epithelial permeability. This study aimed to assess the reliability of ventilation scans with Pertechnegas to evaluate alveolar-capillary permeability. Six non-smokers with no evidence of pulmonary disease were investigated. Scintigraphic data were used to evaluate the site of Pertechnegas deposition (by assessing the Penetration Index [PI] of the gas), its clearance rate (by calculating the time to half-clearance [T1/2]) and its lung distribution (by means of a pixel-by-pixel analysis. PI measurements produced a mean value of 88.8 +/- 13.3% (range 69-117%). Time activity curves showed a fast clearance in all cases (mean T1/2 = 10.7 +/- 2.1 min, range 8.1-14.3 min). Comparison of statistical indices of uniform deposition (skewness and kurtosis) indicated satisfactory homogeneity of Pertechnegas distribution throughout the lungs. These data show that after inhalation Pertechnegas has a peripheral deposition and a homogeneous distribution in the lungs and is rapidly cleared through the alveolar-capillary barrier. In conclusion Pertechnegas can be recommended as a potential radiopharmaceutical for studying the pulmonary epithelial barrier.
BMJ Case …, 2010
A fit, 54-year-old, postmenopausal woman presented with an upper outer quadrant left breast mass ... more A fit, 54-year-old, postmenopausal woman presented with an upper outer quadrant left breast mass in October 2007, for which she underwent conservative surgery. Histology revealed a 27 mm, grade 3, oestrogen receptor (ER) positive, human epidermal growth factor receptor 2 ...
Nuclear Medicine …, 2007
The term 'molecular imaging' encompasses a range of imaging techniques that are aimed a... more The term 'molecular imaging' encompasses a range of imaging techniques that are aimed at visualizing molecular events at a cellular level in a living organism, in a non-invasive approach, to avoid exposing the subject to a surgical risk. Important molecular imaging ...
Diagnostics
Predicting grade 1 (G1) and 2 (G2) primary pancreatic neuroendocrine tumour (panNET) is crucial t... more Predicting grade 1 (G1) and 2 (G2) primary pancreatic neuroendocrine tumour (panNET) is crucial to foresee panNET clinical behaviour. Fifty-one patients with G1-G2 primary panNET demonstrated by pre-surgical [68Ga]Ga-DOTANOC PET/CT and diagnostic conventional imaging were grouped according to the tumour grade assessment method: histology on the whole excised primary lesion (HS) or biopsy (BS). First-order and second-order radiomic features (RFs) were computed from SUV maps for the whole tumour volume on HS. The RFs showing the lowest p-values and the highest area under the curve (AUC) were selected. Three radiomic models were assessed: A (trained on HS, validated on BS), B (trained on BS, validated on HS), and C (using the cross-validation on the whole dataset). The second-order normalized homogeneity and entropy was the most effective RFs couple predicting G2 and G1. The best performance was achieved by model A (test AUC = 0.90, sensitivity = 0.88, specificity = 0.89), followed by ...
Blood
FDG-PET role in the assessment of lymphoma patients is well established but only few papers evalu... more FDG-PET role in the assessment of lymphoma patients is well established but only few papers evaluated the usefulness of FDG-PET during follow up. Aim: to prospectively investigate the value of serial FDG-PET scans in the follow up of lymphoma patients in complete remission. All lymphoma patients who achieved a complete remission were prospectively enrolled in the study and scheduled for serial FDG-PET scans at 6, 12, 18 and 24 months; further scans were then carried out on annual basis (overall 421 pts, 160 pts with Hodgkin’s Disease (HD) and 261 pts with non-Hodgkin Lymphoma (NHL) were studied). All patients had a final assessment using other imaging procedures and/or biopsy and/or clinical evolution. FDG-PET findings were reported as positive, indeterminate or negative for relapse; after comparison with all available data, PET results were categorized as true positive (TP), true negative (TN), false positive (FP), indeterminate turned out to be relapse (I+) and indeterminate turne...
Seminars in nuclear medicine, 2016
Conventional anatomical imaging with CT and MRI has limitations in the evaluation of prostate can... more Conventional anatomical imaging with CT and MRI has limitations in the evaluation of prostate cancer. PET is a powerful imaging technique, which can be directed toward molecular targets as diverse as glucose metabolism, density of prostate-specific membrane antigen receptors, and skeletal osteoblastic activity. Although 2-deoxy-2-(18)F-FDG-PET is the mainstay of molecular imaging, FDG has limitations in typically indolent prostate cancer. Yet, there are many useful and emerging PET tracers beyond FDG, which provide added value. These include radiotracers interrogating prostate cancer via molecular mechanisms related to the biology of choline, acetate, amino acids, bombesin, and dihydrotestosterone, among others. Choline is used for cell membrane synthesis and its metabolism is upregulated in prostate cancer. (11)C-choline and (18)F-choline are in wide clinical use outside the United States, and they have proven most beneficial for detection of recurrent prostate cancer. (11)C-acetat...